Please ensure Javascript is enabled for purposes of website accessibility

Why This Marijuana Stock Crashed 18% in December

By Todd Campbell - Jan 9, 2016 at 12:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Following a string of disappointments, marijuana medicine may be losing its luster with investors.

Image source: GW Pharmaceuticals plc.

What: Despite reporting encouraging data regarding a marijuana-derived medicine for epilepsy, shares in GW Pharmaceuticals plc (GWPH) slid 17.5% last month, according to Capital IQ.

So what: Marijuana drug research was dealt a series of blows at GW Pharmaceuticals in 2015 that included the high-profile failure of the THC based drug Sativex for cancer pain and disappointing results for a CBD-based drug for schizophrenia.

The inability to deliver positive efficacy in placebo-controlled studies in these indications trumped somewhat encouraging epilepsy data reported by the company last month.

Specifically, on December 7, GW Pharmaceuticals highlighted physician reports of fewer seizures in epilepsy patients receiving the company's Epidiolex in an expanded access study. Patients in this study were seen to have a median 45% reduction in seizures after 12 weeks of treatment.

Now what: U.K.-based GW Pharmaceuticals is in a horse race with U.S.-based Insys Therapeutics (INSY), which is also working on a CBD treatment for epilepsy.

Results from GW Pharmaceuticals' and Insys Therapeutics' ongoing phase 3 studies in Dravet syndrome and Lennox-Gastaut syndrome -- two rare forms of the condition -- are expected this year, and if those results are solid, then the two companies could face off against each another in a battle for market share as early as 2017.

However, because the patient population targeted by these marijuana medicines is small, the commercial opportunity -- at least at the onset -- may not be enough to justify GW Pharmaceuticals' current $1.4 billion market cap. For that reason, investors may be better off sitting this one out until data from both companies is reported and there's more insight into who may have an edge, commercially.

Todd Campbell owns shares of INSYS THERAPEUTICS INC. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

INSYS Therapeutics Stock Quote
INSYS Therapeutics
GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.